Top

Published in:

Open Access 01-01-2018 | Clinical Guides in Oncology

SEOM clinical guidelines for anaplastic gliomas (2017)

Authors: C. Balañá, M. Alonso, A. Hernandez, P. Perez-Segura, E. Pineda, A. Ramos, A. R. Sanchez, P. Teixidor, E. Verger, M. Benavides

Published in: Clinical and Translational Oncology | Issue 1/2018

Abstract

The SEOM/GEINO clinical guidelines provide recommendations for radiological, and molecular diagnosis, treatment and follow-up of adult patients with anaplastic gliomas (AG). We followed the 2016 WHO classification which specifies the major diagnostic/prognostic and predictive value of IDH1/IDH2 missense mutations and 1p/19q codeletions in AG. The diagnosis of anaplastic oligoastrocytoma is discouraged. Surgery, radiotherapy and chemotherapy with PCV or TMZ are the first-line standard of care for AG with slight modifications according to molecular variables. A multidisciplinary team is highly recommended in the management of these tumors.

Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the US in 2008-2012. Neuro Oncol. 2015;17(Suppl 4):iv1–62. doi:10.1093/neuonc/nov189.CrossRefPubMedPubMedCentral

Berrocal A, Gil M, Gallego Ó, Balaña C, Segura PP, García-Mata J, et al. SEOM guideline for the treatment of malignant glioma. Clin Transl Oncol. 2012;14(7):545–50. doi:10.1007/s12094-012-0839-6.CrossRefPubMed

Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, et al. Consensus recommendations for a standardized brain tumor imaging protocol in clinical trials. Neuro Oncol. 2015;17(9):1188–98. doi:10.1093/neuonc/nov095.PubMedPubMedCentralCrossRef

Patel P, Baradaran H, Delgado D, Askin G, Christos P, John Tsiouris A, et al. MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis. Neuro Oncol. 2017;19(1):118–27. doi:10.1093/neuonc/now148.CrossRefPubMed

Wang Q, Zhang H, Zhang J, Wu C, Zhu W, Li F, et al. The diagnostic performance of magnetic resonance spectroscopy in differentiating high-from low-grade gliomas: a systematic review and meta-analysis. Eur Radiol. 2016;26(8):2670–84. doi:10.1007/s00330-015-4046-z.CrossRefPubMed

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20. doi:10.1007/s00401-016-1545-1.CrossRefPubMed

Sahm F, Reuss D, Koelsche C, Capper D, Schittenhelm J, Heim S, et al. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol. 2014;128(4):551–9. doi:10.1007/s00401-014-1326-7.CrossRefPubMed

Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol. 2015;129(1):133–46. doi:10.1007/s00401-014-1370-3.CrossRefPubMed

Sanai N, Berger MS. Extent of resection influences outcomes for patients with gliomas. Rev Neurol (Paris). 2011;167(10):648–54. doi:10.1016/j.neurol.2011.07.004.CrossRefPubMed

10.

Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7(5):392–401. doi:10.1016/S1470-2045(06)70665-9.CrossRefPubMed

11.

De Witt Hamer PC, Robles SG, Zwinderman AH, Duffau H, Berger MS. Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. J Clin Oncol Off J Am Soci Clin Oncol. 2012;30(20):2559–65. doi:10.1200/jco.2011.38.4818.CrossRef

12.

Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978;49(3):333–43. doi:10.3171/jns.1978.49.3.0333.CrossRefPubMed

13.

Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980;303(23):1323–9. doi:10.1056/NEJM198012043032303.CrossRefPubMed

14.

Laperriere N, Zuraw L, Cairncross G. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol. 2002;64(3):259–73.CrossRefPubMed

15.

Niyazi M, Brada M, Chalmers AJ, Combs SE, Erridge SC, Fiorentino A, et al. ESTRO-ACROP guideline target delineation of glioblastomas. Radiother Oncol. 2016;118(1):35–42. doi:10.1016/j.radonc.2015.12.003.CrossRefPubMed

16.

Wick W, Roth P, Hartmann C, Hau P, Nakamura M, Stockhammer F, et al. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro Oncol. 2016;18(11):1529–37. doi:10.1093/neuonc/now133.PubMedPubMedCentralCrossRef

17.

Chang S, Zhang P, Cairncross JG, Gilbert MR, Bahary JP, Dolinskas CA, et al. Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813. Neuro Oncol. 2017;19(2):252–8. doi:10.1093/neuonc/now236.PubMedCrossRef

18.

Bent MJVD, Erridge S, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, et al. Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial. J Clin Oncol. 2016; 34(18_suppl):LBA2000-LBA. doi:10.1200/JCO.2016.34.18_suppl.LBA2000.

19.

Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017;. doi:10.1016/S1470-2045(17)30194-8.CrossRefPubMed

20.

Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1994;12(10):2013–21.CrossRefPubMed

21.

van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31(3):344–50. doi:10.1200/JCO.2012.43.2229.CrossRefPubMed

22.

Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31(3):337–43. doi:10.1200/JCO.2012.43.2674.CrossRefPubMed

23.

Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, et al. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol. 2011;13(6):649–59. doi:10.1093/neuonc/nor040.CrossRefPubMedPubMedCentral

24.

Perry JR, Belanger K, Mason WP, Fulton D, Kavan P, Easaw J, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: rESCUE study. J Clin Oncol. 2010;28(12):2051–7. doi:10.1200/JCO.2009.26.5520.CrossRefPubMed

25.

Brada M, Stenning S, Gabe R, Thompson LC, Levy D, Rampling R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol. 2010;28(30):4601–8. doi:10.1200/JCO.2009.27.1932.CrossRefPubMed

26.

Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol. 1999;17(9):2762–71.CrossRefPubMed

27.

Chamberlain MC, Johnston S. Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma. J Neurooncol. 2009;91(3):359–67.CrossRefPubMed

28.

Chamberlain MC, Johnston S. Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer. 2009;115(8):1734–43. doi:10.1002/cncr.24179.CrossRefPubMed

29.

Pitter KL, Tamagno I, Alikhanyan K, Hosni-Ahmed A, Pattwell SS, Donnola S, et al. Corticosteroids compromise survival in glioblastoma. Brain. 2016;139(5):1458–71. doi:10.1093/brain/aww046.CrossRefPubMedPubMedCentral

30.

Weller M, Stupp R, Wick W. Epilepsy meets cancer: when, why, and what to do about it? Lancet Oncol. 2012;13(9):e375–82. doi:10.1016/S1470-2045(12)70266-8.CrossRefPubMed

31.

Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963–72. doi:10.1200/JCO.2009.26.3541.CrossRefPubMed

32.

Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, et al. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol. 2016;. doi:10.1093/neuonc/now058.CrossRefPubMedPubMedCentral

Title: SEOM clinical guidelines for anaplastic gliomas (2017)
Authors: C. Balañá
M. Alonso
A. Hernandez
P. Perez-Segura
E. Pineda
A. Ramos
A. R. Sanchez
P. Teixidor
E. Verger
M. Benavides
Publication date: 01-01-2018
Publisher: Springer International Publishing
Published in: Clinical and Translational Oncology / Issue 1/2018
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-017-1762-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2018

Correction to: SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017)

SEOM clinical guideline for treatment of kidney cancer (2017)

SEOM clinical guideline for the management of malignant melanoma (2017)

SEOM clinical guideline on unknown primary cancer (2017)

SEOM clinical guidelines for endometrial cancer (2017)

SEOM clinical guidelines for the treatment of head and neck cancer (2017)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer